- GTHX -3.51%
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit
Yahoo Finance · 6 days ago
Incyte
Search results
Apr 17, 2024 · Learn more about our culture and benefits, and explore career opportunities with us. G1 Therapeutics, Inc. is a commercial stage oncology company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer.
- 3.8499Add to watchlist-0.1401 (-3.51%)As of Thu. Apr 25, 2024 1:05 PM EDT · Nasdaq Real Time Price (USD) · Market open
- Open4.1900High3.9300Low3.7750
- Mkt Cap200.96MP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close3.990052 Wk. Low1.080052 Wk. High5.0000
Top stories
Related stocks
G1 Therapeutics, Inc. is an American biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company specializes in developing and commercializing small molecule therapeutics for the treatment of patients with cancer.
Mar 1, 2024 · Investors. Overview. G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib).
Click to learn about the trilaciclib mechanism of action. G1 is advancing its lead clinical compound trilaciclib, a first-in-class therapy designed to improve outcomes for patients with certain cancers, in clinical trials assessing combinations with cytotoxic therapies including antibody-drug conjugates (ADCs) and/or immunotherapy in areas of ...
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved COSELA™ (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when adm...
Feb 28, 2024 · G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights. February 28, 2024 at 6:30 AM EST. - Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million -
Feb 12, 2024 · G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib).
